Loading…
Loading…
BIO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BIO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIO and 80,000+ other tickers.
See exactly how BIO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIO and 80,000+ other tickers.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical…
Assetmark Inc. boosted its stake in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 19.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,989 shares of the medical research company's stock after purchasing an additional 6,224 shares during the quarter.
VANCOUVER, BC, Canada – TheNewswire - July 17, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) (“Noveris” or the “Company”) is pleased to announce that it has joined the Biotechnology Innovation Organization (“BIO”), the world's largest advocacy association representing biotechnology companies, academic and research institutions, state and regional biotechnology centers and related organizations across the United States and in more than 35 other countries. By joining BIO, Noveris is strengthening its participation in the global biotechnology ecosystem and expanding opportunities to engage with industry leaders, strategic partners, investors and policymakers across the United States and internationally. The Company believes that membership in BIO will support greater visibility for Noveris within the broader biotechnology and life sciences community while providing access to BIO's policy committees, investor and partnering events, industry research and cost-savings programs that help foster collaboration and commercialization.
HOLMDEL, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, today announced that The Nasdaq Stock Market LLC has notified it that the trading of its common stock will recommence on the Nasdaq Capital Market effective with markets' opening on Wednesday, July 8, 2026.
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026.
BIO-key (BKYI) a global leader in biometric-powered identity & access management to participate at Jordan Banking Cybersecurity Workshop in Amman, July 6.